New Low-dose Irradiation Therapy Combo Shows Positive Effects in Fibromyalgia Animal Model

New Low-dose Irradiation Therapy Combo Shows Positive Effects in Fibromyalgia Animal Model
In an animal model for fibromyalgia, researchers showed that combining low-dose irradiation with the FDA-approved drug Cymbalta (duloxetine) may be a potential strategy for managing fibromyalgia symptoms. The study, “Evidences for amelioration of reserpine-induced fibromyalgia in rat by low dose of gamma irradiation and duloxetine,” was published in the International Journal of Radiation Biology. Cymbalta was approved by the U.S. Food and Drug Administration for the treatment of pain associated with fibromyalgia, among other indications, and belongs to the class of serotonin/norepinephrine reuptake inhibitors (SNRIs). The drug is also approved for the treatment of depression and generalized anxiety disorder, and may be prescribed when mood problems are a serious symptom of fibromyalgia. In the study, a team of researchers investigated whether low-dose irradiation alone or in combination with Cymbalta exerts a therapeutic effect in fibromyalgia. Low-dose irradiation has been shown to improve symptoms in patients with many disorders, including neuronal damages. Researchers tested both therapeutic approaches (low-dose irradiation alone vs. low-dose irradiation plus Cymbalta) in an experimental model of fibromyalgia induced by reserpine in rats. (Reserpine is used to treat high blood pressure, agitation associated with certain conditions like schizophrenia, and other conditions.) They first induced fibromyalgia by administering reserpine to rats for three consecutive days. Cymbalta was given to rats one hour before a forced swimming test (FST), and rats were exposed to a single dose o
Subscribe or to access all post and page content.